Thomas J. Schiessle
EUR 190.00 For Business Accounts Only

„Tafa“(Monjuvi®) Launch in den USA beschleunigt - Cash

Der EQUI.TS-Projektwert steigt nach der schnellen Aufnahme von Monjuvi® in 08/20 in die US-Behandlungsrichtlinien (prominente 2A-Kennzeichnung in der US-NCCN) für die Zweitlinien-Kombi-Behandlung bei R/R DLBCL. Erste Umsätze in 2020 werden u.E. möglich. Damit wird die nun bestätige Guidance 2020 u.E. „konservativ“.

MorphoSys AG

MorphoSys is engaged in development and commercialization of antibodies for therapeutic applications. Co. operates in two segments: Partnered Discovery, which operates therapeutic development programs for drug candidates in cooperation with biotechnology and pharmaceutical companies; and Proprietary Development, which is engaged in the development of therapeutic antibodies in the area of inflammatory disease and oncology on a proprietary basis. As of Dec 31 2013, Co.'s proprietary antibody compounds in clinical trials included MOR103 in the areas of rheumatoid arthritis and multiple sclerosis; MOR202 in the field of multiple myeloma; and MOR208 in the field of malignant B-cell diseases.


EQUI.TS GmbH is an innovative, equity research boutique based in Frankfurt (Germany). It is operated by its original founders and has established a reputation as a quality research provider over a period of more than 10 years. Although it generally does not focus on any particular branch of industry, its analyses often revolve around technology and growth stocks.

Thomas J. Schiessle

Other Reports on these Companies
Other Reports from EQUITS GmbH
Other Reports from these Analysts

ResearchPool Subscriptions

Get the most out of your insights

Get in touch